However, IL-17A is involved in multiple neuroinflammatory conditions, such as MS and stroke [24,28], which share common IL-17 pathways during inflammation; this raises questions about the specificity of IL-17 inhibition as a treatment approach for AD. Here, IL17A is linked to myeloid sarcoma.